Introduction
Multiple myeloma (MM) is a common haematological malignancy of bone marrow plasma cells. The median survival with standard-dose chemotherapy regimens is about 3 years and has not changed significantly in the last 20 years. 1 The most commonly used treatment regimen consists of intermittent oral melphalan and prednisone. Using this drug combination approximately 50% of patients have a resolution in symptoms and a fall in measurable parameters of disease activity to a stable level thus achieving a 'plateau phase' of variable duration (rarely Ͼ12-18 months). 1 Occasional patients (Ͻ5%) achieve a state of complete remission (CR) ie an absence of detectable disease. Aggressive chemotherapy has been shown to be associated with a greater likelihood of achieving an initial 'plateau' phase (70-80%) but is associated with only a marginal survival advantage compared to less intensive chemotherapy. 2 High-dose chemoradiotherapy supported with autologous bone marrow transplantation (ABMT) has been shown, in a randomised multicentre trial, to improve complete remission (CR) rates and survival when compared to standard-dose chemotherapy. 3 Based on this observation high-dose therapy is being increasingly utilised as first-line therapy in younger (age Ͻ70 years) MM patients. Unfortunately, despite improved disease-free survival following highdose therapy relapse is invariable 4 and subsequent salvage treatment options are limited.
Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a member of the TNF family with high homology to fas ligand (fasL). 5 Based on murine 6 and non-human primate 7 data suggesting that TRAIL is harmless to normal cells it has been proposed that TRAIL would be an ideal candidate as an anti-cancer agent. 5 However, a recent report demonstrating that TRAIL effectively induces apoptosis of human hepatocytes in vitro indicates that a better understanding of the therapeutic potential and mechanism of action of TRAIL is required if clinical trials are to be considered. 8 There are four cell surface receptors described for TRAIL: DR4, 9 KILLER/DR5/TRICK-2, 10-14 TRID/DcR1/TRID/LIT, 10, 11, 15, 16 and DcR2/TRUNDD 17, 18 that have been named TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4, respectively. Additionally, osteoprotegerin (OPG) can be used to block TRAIL-induced apoptosis in vitro and is thus considered a soluble receptor. 19 TRAIL-R1 and TRAIL-R2 contain cytoplasmic death domains capable of transducing an apoptotic signal, whereas, neither TRAIL-R3 nor TRAIL-R4 contain such a domain and cannot mediate apoptosis upon binding to TRAIL. The latter two 'decoy' receptors are highly expressed on non-malignant cells and were originally thought to protect them from the apoptotic effects of TRAIL by some form of dominant-negative mechanism. 10, 11, 16 However, some melanoma tumour cells which undergo TRAIL-induced apoptosis also express decoy receptors and this observation has led to the conclusion that the presence of TRAIL-R1 or TRAIL-R2 is necessary and sufficient to mediate cell death. 20 Some human MM cell lines have been shown to be sensitive to apoptosis induced by TRAIL, even though normal B lymphocytes are not. [21] [22] [23] Furthermore, recently published work using purified primary MM tumour cells demonstrated that a leucine zipper construct of TRAIL (LZ-TRAIL) induced features of early apoptosis as evidenced by annexin V staining on up to 87% of primary tumour cells in six patient specimens examined, whereas haemopoietic progenitor cells were unharmed. 24 In an attempt to more clearly define the potential therapeutic role of TRAIL in the management of MM we have examined the efficacy of two different forms of TRAIL to eradicate primary MM tumour cells from bone marrow specimens from a larger group of MM patients. Furthermore, we have examined the relationship between TRAIL receptor expression and TRAIL sensitivity in both cell lines and primary tumour cells.
Materials and methods

TRAIL
Purified human recombinant soluble TRAIL (S-TRAIL), comprising residues 114-281, was purchased from Biomol (Plymouth Meeting, PA, USA). LZ-TRAIL (lot 7367-056 in storage buffer consisting of 25 mm Tris, 1% sucrose, 200 mm NaCl, 0.006% Tween 20, pH 7.4) was kindly supplied by Immunex Corporation (Seattle, WA, USA).
Cell lines -TRAIL-induced apoptosis
The acute T cell lymphoblastic leukaemia Jurkat (J6) human cell line was originally obtained from M Crumpton of the Imperial Cancer Research Fund, London, UK. The MC/CAR cell line and the NCI H929 cell line were purchased from the ATCC (Rockville, MD, USA). The U266 and RPMI 8226 cell lines were kindly supplied by R Brown, Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia. The NCI H929, U266, RPMI 8226 and Jurkat lines were grown in RPMI 1640, whereas the MC/CAR cell line was cultured in IMDM. All medium contained antibiotics, glutamine and was supplemented with 10% FCS.
The cell lines were treated by incubating 2.5 × 10 5 cells/well in 24-well plates with S-TRAIL or LZ-TRAIL at concentrations ranging from 0 g/ml to 5 g/ml in complete medium for 24 h at 37°C, 5% CO 2 . Additional experiments to establish whether inhibition of TRAIL-induced apoptosis of MM cells could be mediated by normal bone marrow (BM) mononuclear cells (MNC) via cell to cell contact or the secretion of an inhibitory substance were also undertaken. In these experiments, TRAIL-sensitive NCIH929 cells were seeded into normal BM MNC and treated overnight with either 1 g/ml LZ-TRAIL or 2 g/ml S-TRAIL with appropriate untreated negative controls. Subsequently, the relative reduction in MM tumour cell numbers was evaluated as described below with the expectation that no inhibition would be detected. Induction of apoptosis in the MM cell lines was quantified by flow cytometric detection of sub-diploid nuclei after propidium iodide staining. Briefly, cells were fixed in ice-cold 70% ethanol and stored at 4°C for a minimum of 24 h. Cells were pelleted and resuspended in 50 g/ml propidium iodide in PBS containing 200 g/ml RNAse A (Sigma, St Louis, MO, USA) and incubated for 1 h at 37°C. Samples were stored at 4°C and analysed on the same day by flow cytometry. The sub-G1 fraction was determined by plotting red fluorescence on a linear scale and the percentage of cells quantified using WinList (Verity Software House, Topsham, ME, USA). Additionally, analysis of DNA fragmentation was achieved using the method of Spector et al, 25 and individual apoptotic cells were visualised by fluorescence microscopy after labelling of DNA strand breaks using the Apoptosis Detection System, Fluorescein (Promega, Madison, WI, USA) as per the manufacturer's instructions. cycles. All PCR cycles also included 95°C pre-heating and final extension at 72°C for 10 min. The primers used were as previously published. [26] [27] [28] Because of the increased quantity of cDNA and cycling required to detect TRAIL-R3, an aliquot of mRNA from each specimen was run in parallel using the TRAIL-R3 primers to exclude false positive amplification due to contaminating genomic DNA. In all instances no signal was detected (data not shown).
Cell lines -TRAIL receptor expression
To confirm amplification of expected cDNA fragments, specific cDNA probes for TRAIL-R1, R2, R3, R4 and OPG were prepared using standard techniques. Briefly, RT-PCR was undertaken as described above utilising mRNA from the cell lines U266 and MC-CAR. The primary RT-PCR products of interest (TRAIL-R1, R2, R3, R4 and OPG) (453 to 612 bp) were eluted and sequenced with ABI PRISM BigDye Terminator (sequencing reaction) and a PE Applied Biosystems 373 STRETCH DNA Sequencer (electrophoresis and analysis). This confirmed the expected specific sequence of each of the RT-PCR products that were then used as PCR templates for the DIG-labelled probe preparation. PCR amplifications were performed in 100 l reactions containing 5 ng DNA template; 12 mm Tris (PH 8.3); 60 mm KCl; 1.5 mm MgCl 2 ; 100 m DigdUTP PCR labelling mixture (Boehringer Mannheim); 0.5 m of each primer and 1 unit Taq DNA polymerase (Boehringer Mannheim). Amplification was carried out on a programmable heating block (Perkin Elmer) by pre-heating at 94°C for 5 min, then 40 cycles of denaturation at 94°C for 1 min, annealing at 50°C for 1 min, and extension at 72°C for 1 min, followed by final extension at 72°C for 10 min.
Finally, 10 l of each primary RT-PCR product was electrophoresed through a 1.5% agarose gel and then transferred to Hybond N+ nylon membrane (Amersham, Cambridge, UK) by alkaline transfer. The membranes were then pre-hybridised for 1 h at previously determined temperatures (OPG 60°C; TRAIL-R1, R2, R3 and R4, 55°C) in hybridisation buffer containing 50% deionized formamide, 5 × SSC, 2% blocking reagent, 0.02% SDS and 0.1% N-lauroylsarcosine. Following addition of heat-denatured Dig-labelled DNA probe, overnight hybridisation was then carried out at the above temperatures. After high stringency washes (2 × SSC 10 min, 2 × SSC/0.1% SDS 10 min, 0.2 × SSC/0.1% SDS 10 min × 2 and 0.1 × SSC/0.1% SDS 15 min × 2 at 55°C) the DNA signal was visualised using ECL reagent (Amersham) and exposure to radiographic film.
TRAIL treatment of BM MNC
Sixteen MM BM aspirates were collected into RPMI/heparin after appropriate informed patient consent was obtained as per institutional guidelines. Patients were at diagnosis (n = 5), after standard-dose chemotherapy (n = 5) or after high-dose chemotherapy with single agent melphalan (200 mg/m 2 ) and autologous peripheral blood stem cell rescue (n = 6). The MNC fraction was isolated by density gradient centrifugation over Lymphoprep (Nycomed Pharma, Oslo, Norway) as per the manufacturer's instructions. The MNC (5 × 10 6 cells) were then split into two aliquots and resuspended at a concentration of 2 × 10 6 cells/ml in RPMI 1640 supplemented with 10% FCS. One aliquot from each patient had added 1 g/ml LZ-TRAIL or 2 g/ml S-TRAIL whilst the paired control aliquot received an equal volume of TRAIL storage buffer or was left untreated, respectively. All cells were incubated at 37°C, 5% CO 2 for 24 h. Dead cells were removed by density gradient centrifugation over Lymphoprep.
Subsequently, the percentage of primary tumour cells in TRAIL-treated and untreated control MNC suspension cultures was determined by staining 10 5 cells for 15 min at room temperature with anti-CD138-FITC (clone MCA681; Serotec, Oxford, UK) or a FITC-conjugated isotype control (PharMingen) at concentrations recommended by the respective manufacturers. The relative reduction in CD138
+ cells within the TRAIL-treated cultures was calculated. As the TRAIL-treated and untreated controls from each patient BM MNC population were treated in an identical fashion any difference in CD138 cell numbers must have been attributable to TRAIL-induced MM cell death or apoptosis (with subsequent loss of CD138 expression).
Enumeration of CD34 + cells in TRAIL-treated and untreated control MNC suspension cultures was achieved using StemKit (Immunotech/Coulter, Marseille, France) as per the manufacturer's instructions. For both CD34
+ and CD138 + enumeration, a minimum of 5000 cells was analysed on an EPICS profile II (Coulter Electronics, Sydney, Australia). Additionally, BM MNC were plated at a concentration of 4 × 10 4 cells/ml in 1 ml aliquots of Methocult GF H4534 (Stem Cell Technologies, Vancouver, Canada) and incubated at 37°C, 5% CO 2 for 14 days. The number of colonies containing at least 50 cells was enumerated and the average of duplicate assays recorded.
Primary tumour cells -TRAIL receptor expression
Primary tumour cells from five of the 16 patients were purified using CD138
+ microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as per the manufacturer's instructions to enable the analysis of TRAIL receptor expression. Primary tumour cell purities of 92% to 97% were obtained (data not shown). RT-PCR and hybridisations were then carried out for TRAIL receptors as described above for the MM cell lines.
Results
Cell lines -TRAIL-induced apoptosis
TRAIL dose-response curves for the five cell lines were generated by quantifying the percentage of sub G1 cells obtained after PI stained cells were analysed by flow cytometry. For the TRAIL-sensitive control Jurkat cells a maximum of 65% to 70% sub-G1 cells was achieved at 1 g/ml LZ-TRAIL ( Figure 1a ) and 2 g/ml S-TRAIL (Figure 1b) . The MM cell lines RPMI 8226 and NCI H929 exhibited levels of approximately 30% to 50% sub-G1 cells at these concentrations. In contrast, MC/CAR and U266 (both Ͻ20% apoptosis) were relatively resistant at similar TRAIL concentrations with no further increase in apoptosis seen with TRAIL concentrations as high as 5 g/ml (data not shown). The features of cell death were examined to confirm that TRAIL was inducing apoptosis in the susceptible cell lines. Electrophoresis of DNA extracted from the target cells revealed a distinct pattern of nucleosomal-sized bands typical of cells undergoing apoptosis in the susceptible lines, whereas the DNA remained intact in the resistant lines (Figure 2 ). These results were confirmed by TUNEL staining which identified cells with fragmented DNA in the Jurkat, NCI H929 and RPMI 8226 cells treated with TRAIL ( Figure 3) . Morphologically, these cells appeared smaller than the control-treated cells, and their nuclei were
Figure 1
Dose-response curves for the cell lines following 24 h exposure to increasing concentrations of LZ-TRAIL (0.05 g/ml to 2 g/ml) (a) or S-TRAIL (0.1 g/ml to 2 g/ml) (b). Values shown are means derived from three separate experiments for each cell line except S-TRAIL NCI H929 and MC-CAR which represent the results from single experiments. Error bars have been omitted to improve clarity.
Figure 2
Electrophoresis of DNA extracted from the cell lines treated with 1 g/ml LZ-TRAIL revealed a distinct pattern of nucleosomal-sized bands typical of cells undergoing apoptosis for Jurkat, RPMI 8226 and NCI H929 whereas the DNA remained intact in the resistant lines U266 and MC/CAR. condensed and fragmented in a manner characteristic of apoptotic cells. Co-cultures of normal BM MNC containing 25% NCI H929 cells treated with TRAIL demonstrated a reduction in CD138 + cells from 25% to 6%, thus confirming the expected reduction in NCI H929 cell numbers with no evidence of a TRAIL inhibitory effect being conferred by coculture with normal BM MNC.
Cell lines -TRAIL receptor expression
RT-PCR and hybridisation for human TRAIL receptors revealed that all four cell lines examined (RPMI 8226, U266, NCI H929 and MC/CAR) expressed mRNA for TRAIL-R1 and TRAIL-R2 (Figure 4 ). This correlated with the detection of cell surface expression for both receptors ( Figure 5 ) as did the detection of TRAIL-R4 mRNA within three of the four lines (resistant cell line U266 was negative for TRAIL-R4). However, despite detection of low levels of mRNA for TRAIL-R3 in all four lines, cell surface detection of the receptor was not detected. At the mRNA level two of four lines also expressed OPG (Figure 4 ). In conclusion, all four cell lines expressed death domain containing TRAIL receptors both at the mRNA level and cell surface but only two of the lines demonstrated TRAIL-induced apoptosis. Furthermore, there was no evidence of an apparent protective effect being conferred by the presence of the decoy or soluble receptors (Table 1) .
TRAIL treatment of BM MNC
Of 16 MM patient BM MNC populations, five (31%) showed у20% reduction of CD138 + cells after TRAIL treatment (Table 2) . Responses were seen with both LZ-TRAIL (n = 3)
Leukemia
Figure 3
TUNEL staining of TRAIL-sensitive Jurkat cells, myeloma cell lines (RPMI 8226, U266 and NCI H929) and the lymphoblastoid cell line MC-CAR after treatment for 24 h with 2 g/ml LZ-TRAIL. Apoptosis of the Jurkat, RPMI 8226 and NCI H929 cells is clearly evident.
and S-TRAIL (n = 2). The specimen from patient 2 at diagnosis showed the greatest response to TRAIL, with a 59% decrease in the number of CD138 + cells, whereas samples from patients 5, 6, 11 and 13 at various stages of treatment showed decreases of 29, 27, 20 and 28%, respectively. The latter included two patients who had achieved sub-optimal responses to high-dose chemotherapy (patients 11 and 13). In accordance with previous studies, neither form of TRAIL had a significant effect on the number of CD34 + cells or on the growth of CFU-GM (Table 2) .
Primary tumour cells -TRAIL receptor expression
RT-PCR data from the primary tumour samples are shown in Figure 6 and summarised in Table 1 . Two of these primary tumours displayed у20% TRAIL-induced reduction in tumour cells (patients 5 and 6). The primary tumour cells from patient 6 expressed mRNA for TRAIL-R1 whereas the tumour cells from patient 5 expressed mRNA from both of the intra-cellular death domain containing TRAIL receptor genes. Both sensitive tumours were also positive for TRAIL-R3, TRAIL-R4 and OPG. Interestingly, compared to the cell lines, expression of TRAIL-R2 was either only weakly expressed or absent within the primary tumours. The three TRAIL-resistant primary tumours (patients 7, 8 and 10) demonstrated mixed expression patterns
Figure 4
Composite figure displaying DIG-labelled hybridisations of TRAIL receptor RT-PCR products from three MM (NCI H929, RPMI 8226 and U266) and one LCL (MC/CAR). All were positive for all four cell surface receptor mRNAs except U266 which was negative for TRAIL-R4. U266 and MC/CAR also expressed mRNA for the soluble TRAIL receptor OPG.
Figure 5
Flow cytometric detection of TRAIL cell surface receptors TRAIL-R1, TRAIL-R2 and TRAIL-R4 on the TRAIL-resistant cell line MC/CAR. Despite the detection of mRNA for TRAIL-R3 no cell surface expression could be detected. The pattern of expression seen is representative of that detected on the other three cell lines (black line, isotype control; grey line, analysed specimen).
( Table 1) . In summary, all five primary tumours displayed varying levels of intra-cellular death domain receptor expression (although in the case of patient 10 only weakly positive) despite three being TRAIL-resistant and both TRAILsensitive primary tumours strongly expressed both of the decoy and soluble TRAIL receptors.
Discussion
The incurability of MM in the overwhelming majority of patients necessitates the ongoing search for alternative more effective therapeutic strategies. Therefore, preliminary cell line data suggesting the therapeutic potential of TRAIL in MM prompted us to evaluate further this apparent activity against MM cell lines and then to test the ability of TRAIL to eradicate primary tumour cells from the BM of MM patients. Furthermore, we sought to identify any correlation between TRAIL receptor expression and TRAIL sensitivity. Of the true MM cell lines that have been tested for TRAIL-induced apoptosis the majority, RPMI 8226, 8226-DOX6, ARP-1, OCI My-5, S6B45 have been shown to be susceptible. 21, 22, 24 To these we can add NCI H929, whereas U266 was resistant to TRAIL-induced apoptosis. The alleged MM cell lines that have previously been shown to be resistant to TRAIL are actually most likely lymphomatous (HS-Sultan) or EBV-transformed B-LCL (IM-9, ARH-77) in origin. 29 Our observation that TRAIL was unable to induce apoptosis in the LCL MC/CAR is consistent with the latter. Concordant results were seen when we tested the two available forms of TRAIL against the cell lines but the crosslinked LZ-TRAIL proved to be a more potent inducer of apoptosis.
We were able to demonstrate a у20% TRAIL-induced reduction in myeloma cells in 31% of the primary tumours that we analysed, with both S-TRAIL and LZ-TRAIL demonstrating efficacy. However, even in primary tumours demonstrating sensitivity to TRAIL the reduction in tumour cell numbers was modest, with a maximum of 59% reduction being seen in one of the previously untreated primary tumours. Of potentially greater significance was that two chemo-resistant post-ASCT primary tumours demonstrated a TRAIL-induced reduction in myeloma cells (patients 11 and 13 with 20% and 28% apoptosis, respectively). Our data contrast with those of Gazitt, 24 who recently reported significant (73% to 87%) LZ-TRAIL-induced apoptosis in six primary MM tumours that he examined using a maximum of 160 ng/ml LZ-TRAIL. Methodological differences between the studies may account for this. In the study reported by Gazitt, primary tumour cells were isolated from BM prior to TRAIL exposure and cells showing features of early apoptosis (annexin V staining) were then manually enumerated with a 500 cell count. It is uncertain whether the cell isolation procedure employed may have sensitised the tumour cells to TRAIL. In contrast, we treated BM MNC suspension cultures and actually quantified the reduction in viable tumour cells flow cytometrically (minimum 5000 cells examined). Preliminary experiments we performed on MM cell lines stained with CD138/annexin V or CD138/PI treated with TRAIL confirmed that loss of CD138 was coincident with annexin V expression and progression to actual cell death and not downregulation of CD138 without subsequent cell death (unpublished observation). Furthermore, it is uncertain that the demonstration of early features of apoptosis with annexin V staining can be taken as unequivocal proof of inevitable cell death, as the study by Gazitt reported 88% apoptosis induction (based on annexin V staining in isolation) in the LCL ARH-77, a result that contrasts markedly with our findings and other investigators who have exposed LCL to higher concentrations of TRAIL and not demonstrated significant cell death. 21, 22 A possible correlation between apoptosis induction and the expression pattern of the known TRAIL receptors was investigated in four cell lines and five patient primary tumours. Concordance between the RT-PCR findings and the cell surface expression of TRAIL-R1, TRAIL-R2 and TRAIL-R4 but not TRAIL-R3 was seen within the cell lines. The necessity for a more sensitive PCR process to detect TRAIL-R3 suggests that in the cell lines we examined TRAIL-R3 was expressed at very low levels and may explain the lack of obvious cell surface expression. The RT-PCR data clearly demonstrate positivity for one or both of the intracellular death domain containing receptors within all nine cell populations (four cell lines, five primary tumours) but only four demonstrated sensitivity (у20% apoptosis) to TRAIL (Table 1) . Furthermore, there appeared to be no relationship between the detection of either of the decoy (TRAIL-R3 and TRAIL-R4) or soluble (OPG) receptors and resistance to TRAIL-induced apoptosis (Table 1) . These findings are in keeping with observations in a study on breast cell lines, 30 melanoma cell lines 20 and paediatric B-ALL, 31 all of which have shown no correlation between TRAIL receptor expression and sensitivity to TRAIL-induced apoptosis. In the latter study, 100% of 29 primary tumour samples expressed all four TRAIL receptors but only 30% Leukemia demonstrated TRAIL-induced apoptosis, findings not dissimilar to ours.
The expression of TRAIL-R1 and/or TRAIL-R2 in the absence of significant TRAIL-induced apoptosis suggests that the receptors may harbour mutations that render them inactive, or alternatively, that TRAIL-related apoptotic pathways may be intracellularly blocked. No data exist about the former. Relevant data addressing possible mechanisms of intra-cellular TRAIL resistance are limited, however, a study by Griffith et al 20 suggests that resistance in melanoma cell lines may be related to the overexpression of an apoptosis inhibitory protein, FLIP (FLICE-inhibitory protein). Furthermore, these authors were able to demonstrate that actinomycin D-induced reductions in intra-cellular concentrations of FLIP correlated with the acquisition of TRAIL sensitivity in previously TRAIL-resistant cell lines. Not suprisingly, in view of what is understood about the mechanism of action of TRAIL, there is no evidence that overexpression of Bcl2 or MDR 21, 24 is associated with TRAIL resistance.
Figure 6
Composite figure displaying DIG-labelled hybridisations of TRAIL receptor RT-PCR products from five primary tumour cell populations. MC/CAR was used as a postive control (not shown). The pattern of mRNA expression was quite variable. No apparent relationship was seen between receptor expression and TRAIL sensitivity with the sensitive tumors P5 and P6 strongly expressing mRNA for the two decoy receptors whereas the TRAIL-resistant tumour P8 was positive for TRAIL-R1 but for neither of the decoy receptors
Multiple myeloma remains a difficult disorder to treat with an expectation that current therapeutic strategies will extend survival for some patients, compared to historical controls, but not provide cure. 32 We have described the efficacy of TRAIL against primary tumour cells derived from a group of 16 MM patients at various stages of therapy. A TRAIL-induced reduction in tumour cells was seen in a significant minority of tumour cell populations examined including those derived from patients with disease resistant to more traditional modes of therapy. We were able to demonstrate the expression of TRAIL receptors in cell lines and primary tumour cells and confirmed the observations in other tumour types that the expression of so-called decoy receptors does not provide protection against TRAIL-induced apoptosis.
The elucidation of the mechanisms underlying the TRAIL resistance demonstrated by some of the primary tumour cells might allow the effective combination of TRAIL with noncross-resistant therapeutic agents. Therefore, if the safety of TRAIL at pro-apoptotic doses in humans can be confirmed, we feel that it may have a potentially useful role as an adjunct to present therapies for MM, particularly in older patients and in those with chemotherapy-resistant disease. We are presently investigating the potential for therapeutic synergy between TRAIL and other anti-tumour agents and evaluating the downstream elements of the TRAIL apoptotic pathway in TRAIL-sensitive and -resistant MM cell lines to further understand the potential mechanisms underlying TRAIL resistance in MM.
